Literature DB >> 6903192

Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement.

M K Pangburn, H J Müller-Eberhard.   

Abstract

The reaction of [14C]methylamine with native human C3 led to the stoichiometric incorporation of methylamine, loss of hemolytic activity, and the concomitant exposure of a sulfhydryl group that could be labeled with [14C]iodoacetamide. Both labeled sites were located in the C3d portion of the alpha-chain, which is known to contain the metastable binding of C3b. The methylamine-modified C3 [C3(CH3NH2)] was shown to exhibit many of the functional properties of C3b, although the C3a portion of the molecule remained covalently attached. C3(CH3NH2) bound Factor B and beta 1H, and could be cleaved by C3b inactivator in the presence of beta 1H. C3(CH3NH2) added to human serum caused activation of the alternative pathway and consumption of C3. In presence of Factors B and D and Mg++, C3(CH2NH2) formed a C3 convertase. The convertase-forming material could be removed from solution by anti-C3a Sepharose and the preformed convertase was completely inhibited by purified antibody to C3a. This antibody did not affect the function of the C3 convertase that contained C3b. Similar functional properties were exhibited by C3 exposed for short periods of time to relatively low concentrations of chaotropic reagents, such as KSCN or guanidine. These results suggest that the initial C3 convertase of the alternative pathway may be formed from native C3, without proteolysis, by the attack of a variety of nucleophiles including water. The C3 convertase formed from this altered C3 then generates by proteolytic cleavage the initial metastable C3b that is capable of attaching to receptive surfaces. Conversion of C3 to C3b exposes one sulfhydryl residue as does modification of C3 with methylamine. When the C3d portion of C3b bound to zymosan particles via the metastable binding site was treated with radiolabeled methylamine, the fragment was released from the particles in radiolabeled form. These findings are consistent with the concept that native C3 contains an active carbonyl group, probably in the form of a thioester, which can either react with water to form functionally C3b-l;ike C3 or, upon enzymatic conversion of C3 to C3b, allows C3b to form an ester bond with hydroxyl groups on the target surface.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6903192      PMCID: PMC2185963          DOI: 10.1084/jem.152.4.1102

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  28 in total

1.  The alternate pathway of complement activation. The role of C3 and its inactivator (KAF).

Authors:  P A Nicol; P J Lachmann
Journal:  Immunology       Date:  1973-02       Impact factor: 7.397

2.  Isolation of the anticomplementary protein from cobra venom and its mode of action on C3.

Authors:  H J Müller-Eberhard; K E Fjellström
Journal:  J Immunol       Date:  1971-12       Impact factor: 5.422

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Solubilization of particulate proteins and nonelectrolytes by chaotropic agents.

Authors:  Y Hatefi; W G Hanstein
Journal:  Proc Natl Acad Sci U S A       Date:  1969-04       Impact factor: 11.205

5.  Hemolytic activity of lipoprotein-depleted serum and the effect of certain anions on complement.

Authors:  A P Dalmasso; H J Müller-Eberhard
Journal:  J Immunol       Date:  1966-11       Impact factor: 5.422

6.  The reaction mechanism of human C5 in immune hemolysis.

Authors:  N R Cooper; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1970-10-01       Impact factor: 14.307

7.  The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation.

Authors:  P J Lachmann; L Halbwachs
Journal:  Clin Exp Immunol       Date:  1975-07       Impact factor: 4.330

8.  Initiation of C3 cleavage in the alternative complement pathway.

Authors:  D T Fearon; K F Austen
Journal:  J Immunol       Date:  1975-11       Impact factor: 5.422

9.  Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor.

Authors:  R D Schreiber; R G Medicus; O Gïtze; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1975-09-01       Impact factor: 14.307

10.  The reaction mechanism of beta-1C-globulin (C'3) in immune hemolysis.

Authors:  H J Müllerèberhard; A P Dalmasso; M A Calcott
Journal:  J Exp Med       Date:  1966-01-01       Impact factor: 14.307

View more
  88 in total

1.  Pseudomonas aeruginosa Psl polysaccharide reduces neutrophil phagocytosis and the oxidative response by limiting complement-mediated opsonization.

Authors:  Meenu Mishra; Matthew S Byrd; Susan Sergeant; Abul K Azad; Matthew R Parsek; Linda McPhail; Larry S Schlesinger; Daniel J Wozniak
Journal:  Cell Microbiol       Date:  2011-11-10       Impact factor: 3.715

Review 2.  Anti-inflammatory effect of intravenous immunoglobulin mediated through modulation of complement activation.

Authors:  Hans U Lutz; Peter J Späth
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

3.  Chylomicron accelerates C3 tick-over by regulating the role of factor H, leading to overproduction of acylation stimulating protein.

Authors:  Takayuki Fujita; Takayuki Fujioka; Tetsuo Murakami; Atsushi Satomura; Yoshinobu Fuke; Koichi Matsumoto
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

4.  The pathogenesis of hyaline arteriolosclerosis.

Authors:  C N Gamble
Journal:  Am J Pathol       Date:  1986-03       Impact factor: 4.307

5.  A C3(H20) recycling pathway is a component of the intracellular complement system.

Authors:  Michelle Elvington; M Kathryn Liszewski; Paula Bertram; Hrishikesh S Kulkarni; John P Atkinson
Journal:  J Clin Invest       Date:  2017-02-13       Impact factor: 14.808

6.  Decay-accelerating factor induction by tumour necrosis factor-alpha, through a phosphatidylinositol-3 kinase and protein kinase C-dependent pathway, protects murine vascular endothelial cells against complement deposition.

Authors:  Saifur R Ahmad; Elaine A Lidington; Rieko Ohta; Noriko Okada; Michael G Robson; Kevin A Davies; Michael Leitges; Claire L Harris; Dorian O Haskard; Justin C Mason
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

7.  Sequence determination of the thiolester site of the fourth component of human complement.

Authors:  R A Harrison; M L Thomas; B F Tack
Journal:  Proc Natl Acad Sci U S A       Date:  1981-12       Impact factor: 11.205

8.  Characterization of the Mr difference between secreted murine fourth component of complement and the major plasma form: evidence for carboxyl-terminal cleavage of the alpha chain.

Authors:  D R Karp; D C Shreffler; J P Atkinson
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

9.  Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles.

Authors:  Yvonne Klapper; Osama A Hamad; Yuji Teramura; Gero Leneweit; G Ulrich Nienhaus; Daniel Ricklin; John D Lambris; Kristina N Ekdahl; Bo Nilsson
Journal:  Biomaterials       Date:  2014-01-23       Impact factor: 12.479

10.  Flavoxobin, a serine protease from Trimeresurus flavoviridis (habu snake) venom, independently cleaves Arg726-Ser727 of human C3 and acts as a novel, heterologous C3 convertase.

Authors:  Chieko Yamamoto; Daisuke Tsuru; Naoko Oda-Ueda; Motonori Ohno; Shosaku Hattori; Sung-Teh Kim
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.